Imago BioSciences welcomes Laurie Keating to its Board of Directors

– USA, CA –  ​Imago BioSciences, Inc. (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms, today announced the appointment of Laurie Keating to its Board of Directors, effective on November 17, 2021.

“I am pleased to welcome to Laurie to Imago’s Board of Directors as the company continues to grow, following our successful IPO in July. Laurie brings extensive experience to our Board and we look forward to leveraging her judgment, skills and know-how as we progress bomedemstat, our novel LSD1 inhibitor, through the regulatory process,” said CEO, Dr. Hugh Young Rienhoff.

About Laurie Keating

Laurie Keating is a seasoned executive, with nearly two decades of her 40-year career in diverse roles within the biopharmaceutical industry.

Laurie Keating most recently served as EVP and Chief Legal Officer at Alnylam Pharmaceuticals, where she led the company’s global public policy and government relations, legal, and intellectual property groups. Before joining Alnylam, Keating served as SVP, General Counsel, and Secretary at Millennium Pharmaceuticals, where she led the legal, intellectual property, corporate quality, and compliance groups. Before Millennium, Keating was the founding CEO of Hydra Biosciences, a privately held, venture-backed company, and served on Hydra’s Board for six years.

“Imago’s advances in the potential treatment of myeloproliferative neoplasms with bomedemstat are highly promising, and I am thrilled to join the company’s Board of Directors at such an exciting time. I look forward to contributing to Imago’s continued growth, and collaborating with the leadership team as we navigate the regulatory and clinical development processes, to bring a much-needed new treatment option to underserved patients,” commented Laurie Keating.

Keating currently sits on the Board of Directors for Immuneering Corporation and MassBIO, a non-profit organization dedicated to growing the biopharmaceutical industry, adding value to the healthcare system, and improving patient lives in Massachusetts.

She has a bachelor’s degree in economics from the University of California, Berkeley, and received her J.D. from the University of California, Hastings College of Law.

About Imago BioSciences

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1, an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small-molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms, a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia and myelofibrosis. Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency Orphan Designation for the treatment of ET and MF, and PRIority MEdicines Designation by the EMA for the treatment of MF. The company is based in South San Francisco, California.

For more information: https://imagobio.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.